[Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]

Gynecol Obstet Fertil. 2007 Feb;35(2):107-13. doi: 10.1016/j.gyobfe.2006.12.010. Epub 2007 Jan 30.
[Article in French]


Objectives: The objectives of this study were to estimate the incidence of genital warts and treatment costs in women consulting gynaecologists in France in 2005.

Patients and methods: A prospective observational study was performed through a representative sample of gynaecologists. Investigators enrolled all patients seen with genital warts during a 2-month period. A questionnaire detailing socio-demographic characteristics, case description, patient's clinical profile, past/ current management, and treatment of genital warts was completed by the investigators.

Results: 212 gynaecologists participated in the study. Questionnaires were completed for 263 patients including 198 (75.3%) new cases, 53 (20.2%) recurrent cases and 12 (4.5%) resistant cases. The overall incidence was estimated at 228.9/100,000 (female 15-65year old population) corresponding to 47,755 cases annually managed by gynaecologists in France. The average treatment cost was 482.70euro for society and 342.40 euro for third-party payers. The annual direct cost of genital warts management was estimated at 23,051,339euro, of which 16,351,312euro was funded by the French health care system.

Discussion and conclusion: The costs of treating genital warts are considerable. The introduction of a quadrivalent (type 6,11,16,18) Human Papillomavirus vaccine including types responsible for 90% of genital warts could potentially substantially reduce these costs.

Publication types

  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Condylomata Acuminata / economics*
  • Condylomata Acuminata / epidemiology*
  • Condylomata Acuminata / prevention & control
  • Cost-Benefit Analysis
  • Female
  • France / epidemiology
  • Health Care Costs*
  • Humans
  • Incidence
  • Middle Aged
  • Papillomavirus Vaccines / administration & dosage*
  • Papillomavirus Vaccines / economics*
  • Prospective Studies


  • Papillomavirus Vaccines